Intercept Pharma (ICPT) Misses Q3 EPS by 8c, Revenues Beat; Offers FY20 Ocaliva Net Sales Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Intercept Pharma (ICPT) Misses Q3 EPS by 8c, Revenues Beat; Offers FY20 Ocaliva Net Sales Mid-Point Guidance Above Consensus

Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update

November 9, 2020 7:00 AM EST

Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter

Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to $310 million to $320 million

Intercept updates 2020 non-GAAP Adjusted Operating Expenses Guidance to narrow the range to $460 million to $480 million

Productive Type A Meeting held with FDA on NASH Fibrosis Program

Conference call scheduled for 8:30 a.m. ET today

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:... More